Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives-Reference-Cited by-同舟云学术

Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives

Published:2017 Issue:1 Volume:11 Page:110-114
ISSN:1881-7815
Container-title:BioScience Trends
language:en
Short-container-title:BST

Author:

Guolo Fabio¹,Minetto Paola¹,Clavio Marino¹,Miglino Maurizio¹,Lemoli Roberto Massimo¹,Gobbi Marco¹

Affiliation:

1. Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine,Health (social science)

Link

https://www.jstage.jst.go.jp/article/bst/11/1/11_2016.01221/_pdf

Reference30 articles.

1. 1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015; 373:1136-1152.

2. 2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391-2405.

3. 3. Döhner H, Estey EH, Amadori S, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.

4. 4. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrag-resistant leukemia cells. Blood. 1992;79:3267-3272.

5. 5. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non lymphocytic leukemias: Biological and clinical implications. Br J Haematol. 1999;104:328-335.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review;International Journal of Molecular Sciences;2021-05-07

2. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden;Cancers;2020-12-24

3. Observation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia;Oncology Letters;2019-01-24

4. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy;Biomedicine & Pharmacotherapy;2018-01